Standardized management of hepatocellular adenomas              YU Lei, ZHOU Jian. Liver Cancer Institute and Zhongshan Hospital, Fudan University; Carcinogenesis and Invasion, Ministry of Education Key Laboratory, Shanghai200032, China
Corresponding author: ZHOU Jian, E-mail：zhou.jian@zs-hospital.sh.cn
Abstract    Hepatocellular adenomas (HCAs) are rare benign liver tumors that commonly occur in young women and strongly associated with the use of oral contraceptive pills. HCAs have no specific manifestation and the diagnoses are mainly made upon imaging and biopsy. Bleeding and malignant transformation are two major complications of HCAs. Thus it needs active surgical strategy to remove the tumor. Recently HCAs are classified into 3 distinct subtypes by molecular biology techniques such as inflammatory HCAs，hepatocyte nuclear factor-1 mutated HCAs and β-catenin activated HCAs. Each subtype has a characteristic histopathology，oncogenesis and so on, which provide evidences for further individualized therapy.